Exploring FABP4 as a Therapeutic Target in COVID‐19 and the Role of Ocimum Sanctum Linn . in Modulating Pathogenesis
ChemistrySelect · 2026-11 · 11 (43)
DOI: 10.1002/slct.202506421 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemistrySelect, online erschienen am 16.11.2026. Verfasst von Vineetha Shaji und 7 weiteren Autor:innen. Die Arbeit nennt 87 Literaturangaben.
Abstract (Originalsprache)
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2), the causative agent of COVID‐19, has been associated with Long COVID, a condition marked by persistent fatigue, respiratory complications, neurological impairments, and systemic inflammation. Recent evidence indicates that fatty acid‐binding protein 4 (FABP4) may play a significant role in SARS‐CoV‐2 pathogenesis, although its involvement in inflammation remains largely unexplored. Despite continued research, the mechanisms behind prolonged inflammatory responses remain unclear, and effective treatments are still under investigation. This study employed molecular docking tools to evaluate the binding efficacy of natural compounds derived from Ocimum sanctum (Tulsi) against FABP4. The objective was to assess FABP4's potential role in SARS‐CoV‐2‐related inflammation. Various computational approaches, including molecular docking, ADMET profiling, MM‐GBSA calculations, and molecular dynamics simulations, were used to identify potent FABP4 inhibitors. Among the compounds, Rutin demonstrated the highest docking score (‐12.30 kcal/mol) and stronger binding affinity to FABP4 compared to the control BMS309403 (‐11.59 kcal/mol). MM‐GBSA analysis further revealed a more favorable binding free energy (ΔG_bind) for Rutin (‐75.08 kcal/mol) relative to the control (‐53.08 kcal/mol). These findings suggest that Rutin may serve as a potent natural FABP4 inhibitor. Given the known anti‐inflammatory and cardiometabolic benefits of BMS309403, Rutin's interaction with FABP4 points to its potential in alleviating Long COVID symptoms. Furthermore, FABP4's interaction with natural compounds like Rutin offers promising insight into therapeutic strategies for inflammation‐driven diseases such as atherosclerosis. This study highlights the therapeutic potential of O. sanctum and reinforces the need for further research into FABP4 as a drug target.
Zitieren
APA
Shaji, V., Banjan, B., Koshy, A. J., Raj, S. S., Prasad, G., R., R. J., Raju, R., & Revikumar, A. (2026). Exploring FABP4 as a Therapeutic Target in COVID‐19 and the Role of Ocimum Sanctum Linn . in Modulating Pathogenesis. ChemistrySelect, 11(43). https://doi.org/10.1002/slct.202506421
Vancouver
Shaji V, Banjan B, Koshy AJ, Raj SS, Prasad G, R. RJ, et al. Exploring FABP4 as a Therapeutic Target in COVID‐19 and the Role of Ocimum Sanctum Linn . in Modulating Pathogenesis. ChemistrySelect. 2026;11(43). doi:10.1002/slct.202506421
BibTeX
@article{Shaji2026,
author = {Shaji, Vineetha and Banjan, Bhavya and Koshy, Abel John and Raj, Sini S. and Prasad, Ganesh and R., Rani J. and Raju, Rajesh and Revikumar, Amjesh},
title = {Exploring FABP4 as a Therapeutic Target in COVID‐19 and the Role of Ocimum Sanctum Linn . in Modulating Pathogenesis},
journal = {ChemistrySelect},
year = {2026},
volume = {11},
number = {43},
doi = {10.1002/slct.202506421}
}
EUVIMED